Global Companion Animal Arthritis Market Size study, by Animal Type (Dogs, Cats, Others), by Animal Type (Dogs, Cats, Others) by Indication (Osteoarthritis, Other Arthritis) by Treatment (Medication, Supplements, Other Treatment) by Distribution Channel (

Global Companion Animal Arthritis Market Size study, by Animal Type (Dogs, Cats, Others), by Animal Type (Dogs, Cats, Others) by Indication (Osteoarthritis, Other Arthritis) by Treatment (Medication, Supplements, Other Treatment) by Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores, Others) and Regional Forecasts 2022-2028

Global Companion Animal Arthritis Market is valued approximately USD 2.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.8 % over the forecast period 2022-2028. Osteoarthritis (OA) is a prevalent disease in dogs and cats. It is classified as a low-grade inflammatory, degenerative joint condition. Some of the important reasons driving the market include the expanding companion animal population, the rising incidence of arthritis, rising risk factors for the illness, supporting awareness campaigns undertaken by governments, and tactics implemented by prominent firms. For example, the American Veterinary Medical Association announced in November 2021 that the companion animal population had expanded considerably between 2016 and 2020. According to the report, the dog population in the United States was expected to be 76.8 million in 2016, with a projected growth to 83.7 million by 2020. Cat population climbed from 58.4 million in 2016 to 60 million in 2020. This is predicted to help the industry flourish. The rising acceptance of pet insurance, higher animal healthcare spending, R&D investments by leading firms, post-pandemic return to normalcy, and the expansion of drug products are some of the key drivers driving market development. According to the Insurance Information Institute, Inc., pet care spending will increase from USD 53.3 in 2012 to USD 123.6 in 2021. In a year, almost USD 1,480 is spent per dog and USD 943 is spent every cat. Similarly, according to FEDIAF, roughly 21.8 billion euros will be spent in Europe in 2020 on pet food and 21.2 billion euros on other pet-related services and goods. These positive characteristics are assisting the market's expansion. However, lack of awareness impedes market expansion throughout the projection period of 2022-2028.

The key regions considered for the Global Companion Animal Arthritis Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America emerged as the market leader. This is attributable to major players' considerable presence, the implementation of numerous initiatives begun by key corporations to improve market penetration, rising treatment availability, rising diagnostic rates, and expanding pet population and spending. Another factor projected to drive market expansion is the increasing number of veterinary clinics in the nations having licensed and qualified veterinarians. The Asia Pacific area is expected to grow at the fastest CAGR over the projection period. This is due to rising animal healthcare expenditure and disposable income in important markets, as well as increased illness awareness in emerging nations. Growing need for thorough and fast diagnosis of companion animal arthritis in emerging nations such as India is driving market expansion.

Major market player included in this report are:
Zoetis
Virbac
Elanco
Boehringer Ingelheim International GmbH
Ceva
Dechra Pharmaceuticals PLC.
Vetoquinol
NexGen Pharmaceuticals
Norbrook
Eltech K-Laser s.r.l.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Animal Type:
Dogs
Cats
Others

By Indication:
Osteoarthritis
Other Arthritis

By Treatment:
Medication
Supplements
Other Treatment

By Distribution Channel:
Veterinary Hospitals & Clinics
Retail Pharmacies
Online Stores
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Companion Animal Arthritis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Zoetis
Virbac
Elanco
Boehringer Ingelheim International GmbH
Ceva
Dechra Pharmaceuticals PLC.
Vetoquinol
NexGen Pharmaceuticals
Norbrook
Eltech K-Laser s.r.l.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.